ストックスクリーナーアプリを入手
2.718
2.16%
-0.062
前日終値:
$2.78
開ける：
$2.79
24時間の取引高:
517.85K
Relative Volume:
1.17
時価総額：
$170.36M
収益：
-
当期純損益:
$-131.52M
株価収益率:
-1.527
EPS:
-1.78
ネットキャッシュフロー:
$-107.56M
1週間 パフォーマンス:
+21.97%
1か月 パフォーマンス:
+34.65%
6か月 パフォーマンス:
+119.35%
1年 パフォーマンス:
+212.32%
1日の値動き範囲:
$2.60
$3.04
1週間の範囲:
$2.06
$3.04
52週間の値動き範囲:
$0.6101
$4.22
Prelude Therapeutics Inc Stock (PRLD) Company Profile
名前
Prelude Therapeutics Inc
セクター
電話
(302) 467-1280
住所
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
2.71 | 174.77M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.79 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.93 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-19 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-20 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 開始されました | Jefferies | Buy |
| 2022-03-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-02-28 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-10-08 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-26 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2020-11-20 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-10-20 | 開始されました | Goldman | Neutral |
| 2020-10-20 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Prelude Therapeutics Inc (PRLD) 最新ニュース
Quarterly Risk: Does Prelude Therapeutics Incorporated have consistent dividend growthJuly 2025 Earnings & Safe Capital Allocation Plans - baoquankhu1.vn
Guidance Update: Is Prelude Therapeutics Incorporated stock trending bullishTreasury Yields & Technical Entry and Exit Alerts - baoquankhu1.vn
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Update - MarketBeat
How Prelude Therapeutics’ deal with Incyte changed its course - Delaware Business Times
What’s the beta of Prelude Therapeutics Incorporated stock2025 AllTime Highs & AI Powered Market Entry Strategies - mfd.ru
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Is Prelude Therapeutics Incorporated a cyclical or defensive stock2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru
Is Prelude Therapeutics Incorporated in a long term uptrendJuly 2025 Market Mood & Technical Buy Zone Confirmation - mfd.ru
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 0.9%Should You Sell? - MarketBeat
Is Prelude Therapeutics Incorporated stock trending bullishWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Prelude Therapeutics Secures FDA Clearance for Key Drug Candidate - AD HOC NEWS
Weekly Buzz: ATYR To Meet With FDA, SGMO Aces Fabry Study, AQST's Anaphylm Gets Rejected - RTTNews
Take Profit: Does Prelude Therapeutics Incorporated have a sustainable dividendTrade Analysis Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Why Did PRLD Stock Surge 13% Today? - Stocktwits
Aug Wrap: Is ETRACS 2xMonthly Pay Leveraged Index ETN benefiting from interest rate changes2025 Market WrapUp & Weekly Stock Breakout Alerts - baoquankhu1.vn
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up - GlobeNewswire
Why did PRLD stock surge 13% today? - MSN
Prelude’s JAK2 V617F inhibitor PRT-12396 gains IND clearance - BioWorld MedTech
Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens - Investing.com Canada
FDA clears Prelude Therapeutics’ IND for JAK2 inhibitor in blood disorders - Investing.com Canada
Prelude Therapeutics (PRLD) Advances Blood Cancer Drug Trial wit - GuruFocus
Prelude Therapeutics Incorporated Receives FDA Clearance of Investigational New Drug Application for PRT12396 - marketscreener.com
Prelude Therapeutics stock surges after FDA clears IND for cancer drug By Investing.com - Investing.com South Africa
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
Prelude Therapeutics stock surges after FDA clears IND for cancer drug - Investing.com India
Prelude Therapeutics receives FDA clearance of investigational new drug application (IND) for PRT12396, a mutant-selective JAK2V617F inhibitor - marketscreener.com
Prelude Therapeutics (PRLD) Gains FDA Approval for Phase 1 Study of PRT12396 - GuruFocus
Prelude Therapeutics Wins FDA IND Clearance for PRT12396 - TipRanks
Prelude Therapeutics Inc FDA Clearance for PRT12396 Phase 1 Study - TradingView
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor - ChartMill
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology - TipRanks
Hedge Fund Bets: Will Prelude Therapeutics Incorporated announce a stock splitJuly 2025 Macro Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Retail investors in Prelude Therapeutics Incorporated (NASDAQ:PRLD) are its biggest bettors, and their bets paid off as stock gained 12% last week - Yahoo Finance
Aug Highlights: Does MAMO outperform in volatile markets2025 Support & Resistance & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Prelude Therapeutics (NASDAQ:PRLD) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Aug Reactions: Can Prelude Therapeutics Incorporated outperform under higher oil pricesQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - baoquankhu1.vn
Market Review: Is Prelude Therapeutics Incorporated a cyclical or defensive stockMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
How Prelude Therapeutics Incorporated stock compares to industry benchmarksPortfolio Risk Report & Free Community Consensus Stock Picks - ulpravda.ru
How Prelude Therapeutics Incorporated stock responds to policy changesMarket Activity Recap & Fast Entry High Yield Stock Tips - ulpravda.ru
Prelude Therapeutics (NASDAQ:PRLD) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Prelude Therapeutics Inc Announces New Clinical Developments - TradingView — Track All Markets
Aug Sentiment: How Prelude Therapeutics Incorporated stock responds to policy changesWeekly Investment Summary & Real-Time Market Sentiment Alerts - Улправда
Will Prelude Therapeutics Incorporated stock reach all time highs in 2025Portfolio Update Report & Expert Verified Movement Alerts - Улправда
Will Prelude Therapeutics Incorporated stock benefit from AI adoptionJuly 2025 Rallies & Free Real-Time Market Sentiment Alerts - Улправда
Quarterly Trades: Is Prelude Therapeutics Incorporated stock positioned well for digital economyStop Loss & Free Daily Entry Point Trade Alerts - ulpravda.ru
Prelude Therapeutics Reshapes Pipeline With Incyte Deal and Strategic Refocus - MSN
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Short Interest Up 28.5% in December - MarketBeat
Bullish Prelude Therapeutics Insiders Rewarded As Their Investment Rises To US$2.75m - Sahm
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 2.1%What's Next? - MarketBeat
Prelude Therapeutics Inc (PRLD) 財務データ
収益
当期純利益
現金流量
EPS
Prelude Therapeutics Inc (PRLD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vaddi Krishna | CEO |
Mar 25 '25 |
Buy |
0.69 |
675,000 |
467,438 |
1,999,296 |
| Vaddi Krishna | CEO |
Mar 21 '25 |
Buy |
0.73 |
15,000 |
10,959 |
1,324,296 |
| Vaddi Krishna | CEO |
Mar 20 '25 |
Buy |
0.73 |
5,416 |
3,950 |
1,309,296 |
| Vaddi Krishna | CEO |
Mar 14 '25 |
Buy |
0.75 |
29,999 |
22,631 |
1,294,774 |
| Vaddi Krishna | CEO |
Mar 17 '25 |
Buy |
0.75 |
9,106 |
6,829 |
1,303,880 |
| Vaddi Krishna | CEO |
Mar 13 '25 |
Buy |
0.72 |
50,000 |
35,820 |
1,264,775 |
| Vaddi Krishna | CEO |
Mar 12 '25 |
Buy |
0.71 |
47,500 |
33,744 |
1,214,775 |
0.88%
0.83%
大文字化:
|
ボリューム (24 時間):